Shots:
- The US FDA has approved the BLA filing for Jemperli for adult patients with dMMR recurrent or advanced solid tumors endometrial cancer, as determined by an FDA-approved test, that has progressed on or following prior treatment with a Pt.-containing regimen
- AnaptysBio has received $20M as milestones upon the FDA’s approval and will receive $45M as regulatory milestones in the US & EU, $165M as sales milestones following achievement of annual sales revenues with royalties range from 8% to 25% of global sales
- Jemperli is currently being evaluated in P-III trials for recurrent or primary advanced EC and stage III or IV non-mucinous epithelial ovarian cancer and is the first AnaptysBio-generated Ab out of 8 to obtain FDA approval
Click here to read full press release/ article | Ref: Globe Newswire | Image: Linkedin
The post GSK’s Jemperli (dostarlimab-gxly) Receives the US FDA’s Approval for dMMR Endometrial Cancer first appeared on PharmaShots.
